Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 286

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 286
---
 to DiamiR’s
CogniMIR test for AD, it is developing a miRNA-based assay for monitoring of progression and severity of Rett Syndrome; a panel of blood
protein biomarkers for MCI and AD; a blood-based miRNA test for Glioblastoma, an aggressive form of brain cancer; and miRNA panels for
lung and GI malignancies.

The following table sets forth
the current clinical status and next development steps for DiamiR’s current “lead products,” along with the date DiamiR
currently believes it will complete such next step towards launching the tests in clinical practice setting.

| Product/Indication                        |     | Status                           |     | Next Step                   |     | Estimated            
 Completion           
 Date of Next Step(1) |
| APOE Genotyping Test/AD(2)                |     | Validated                        |     | Ready for commercial launch |     | Completed            |
| CogniMIR®/MCI & AD                        |     | Test Optimization                |     | Clinical Validation Study   |     | 2H 2026              |
| RETT Syndrome Test                        |     | Clinical Validation Study        |     | Pre-Commercial Activities   |     | 2H 2026              |
| Blood Protein Biomarker Panel/MCI & AD(3) |     | Vendor/Platform Selection        |     | Analytical Validation Study |     | 1H 2026              |
| Glioblastoma Panel                        |     | Proof-of-Concept Study           |     | Analytical Validation Study |     | 1H 2026              |
| Pulmonary Cancer Panel                    |     | Proof-of-Concept Study Completed |     | Analytical Validation Study |     | TBD                  |
| GI Cancer Panel                           |     | Proof-of-Concept Study Completed |     | Analytical Validation Study |     | TBD                  |

| (1) | This is DiamiR’s current estimated completion date       
 for the tasks listed as “next steps” in the table above. |

| (2) | This is a commercial test available through multiple vendors                                                                                   
 that DiamiR has analytically validated in its lab under CLIA requirements, but the current plan is to launch it in conjunction with CogniMIR®, 
 as either a standalone product or part of the CogniMIR® panel.                                                                                 |

| (3) | Multiple vendors offer commercial kits for a number of blood                                                                             
 protein markets;